- Home
- ASBP vs HOTH Comparison
ASBP vs HOTH Comparison
Compare ASBP & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASBP
- HOTH
- Stock Information
- Founded
- ASBP 2021
- HOTH 2017
- Country
- ASBP United States
- HOTH United States
- Employees
- ASBP N/A
- HOTH N/A
- Industry
- ASBP Biotechnology: Pharmaceutical Preparations
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- ASBP Health Care
- HOTH Health Care
- Exchange
- ASBP Nasdaq
- HOTH Nasdaq
- Market Cap
- ASBP 18.7M
- HOTH 15.6M
- IPO Year
- ASBP N/A
- HOTH 2019
- Fundamental
- Price
- ASBP $0.35
- HOTH $1.50
- Analyst Decision
- ASBP
- HOTH Strong Buy
- Analyst Count
- ASBP 0
- HOTH 3
- Target Price
- ASBP N/A
- HOTH $4.00
- AVG Volume (30 Days)
- ASBP 39.9M
- HOTH 1.3M
- Earning Date
- ASBP 11-24-2025
- HOTH 11-11-2025
- Dividend Yield
- ASBP N/A
- HOTH N/A
- EPS Growth
- ASBP N/A
- HOTH N/A
- EPS
- ASBP N/A
- HOTH N/A
- Revenue
- ASBP N/A
- HOTH N/A
- Revenue This Year
- ASBP N/A
- HOTH N/A
- Revenue Next Year
- ASBP N/A
- HOTH N/A
- P/E Ratio
- ASBP N/A
- HOTH N/A
- Revenue Growth
- ASBP N/A
- HOTH N/A
- 52 Week Low
- ASBP $0.20
- HOTH $0.65
- 52 Week High
- ASBP $15.80
- HOTH $3.80
- Technical
- Relative Strength Index (RSI)
- ASBP 46.05
- HOTH 43.30
- Support Level
- ASBP $0.20
- HOTH $1.49
- Resistance Level
- ASBP $0.43
- HOTH $1.62
- Average True Range (ATR)
- ASBP 0.06
- HOTH 0.14
- MACD
- ASBP -0.00
- HOTH -0.05
- Stochastic Oscillator
- ASBP 58.81
- HOTH 3.82
About ASBP Aspire Biopharma Holdings Inc. Common Stock
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).